In patient-derived melanoma cells and autologous tumor-infiltrating lymphocyte co-cultures, scientists profiled transcriptomes and 20 proteins in ~218,000 cells under ~750 perturbations associated with cancer cell-intrinsic immune checkpoint inhibitor resistance
6445218 6VZ3WSQW items 1 apa default asc 1
Frangieh, C. J., Melms, J. C., Thakore, P. I., Geiger-Schuller, K. R., Ho, P., Luoma, A. M., Cleary, B., Jerby-Arnon, L., Malu, S., Cuoco, M. S., Zhao, M., Ager, C. R., Rogava, M., Hovey, L., Rotem, A., Bernatchez, C., Wucherpfennig, K. W., Johnson, B. E., Rozenblatt-Rosen, O., … Izar, B. (2021). Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nature Genetics, 1–10. https://doi.org/10.1038/s41588-021-00779-1 Cite
Knocking down CREB-binding protein or Ku70 induced necrotic and paraptotic cell death as indicated by high-level intracellular reactive oxygen species, cytoplasmic vacuolization, and cell cycle arrest in the S phase.
[Cell Death Discovery]
6606345 4SSUS5IZ items 1 apa default asc 1
Ding, L., Wen, Y., Zhang, X., Zhao, F., Lv, K., Shi, J., Shen, S., & Pan, X. (2021). Transcriptional network constituted of CBP, Ku70, NOX2, and BAX prevents the cell death of necrosis, paraptosis, and apoptosis in human melanoma. Cell Death Discovery, 7(1), 1–15. https://doi.org/10.1038/s41420-021-00417-z Cite
IMD-0354 was confirmed as a potent inhibitor of glutamine uptake that attained sustained low intracellular glutamine levels. Concomitant with its inhibition of glutamine uptake, IMD-0354 attenuated mTOR signaling, suppressed 2D and 3D growth of melanoma cells, and induced cell cycle arrest, autophagy and apoptosis.
[Molecular Cancer Therapeutics]
6606345 Q7TKSID5 items 1 apa default asc 1
Scientists demonstrated that both local tumor ionizing radiation and anti–programmed death ligand 1 treatment decreased tumor-induced Ter cell abundance in the mouse spleen and ARTN secretion outside the irradiation field in an interferon- and CD8+ T cell–dependent manner.
[Science Translational Medicine]
6445218 PCBTU6C4 items 1 apa default asc 1
Hou, Y., Liang, H. L., Yu, X., Liu, Z., Cao, X., Rao, E., Huang, X., Wang, L., Li, L., Bugno, J., Fu, Y., Chmura, S. J., Wu, W., Luo, S. Z., Zheng, W., Arina, A., Jutzy, J., McCall, A. R., Vokes, E. E., … Weichselbaum, R. R. (2021). Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Science Translational Medicine, 13(582). https://doi.org/10.1126/scitranslmed.abb0130 Cite
Researchers showed that 1,2,4-TTB (1 mM) markedly suppressed nigericin- or ATP-induced NLRP3 inflammasome activation, thus decreased caspase-1 activation and IL-1β secretion in immortalized murine bone marrow-derived macrophages (iBMDMs) and in primary mouse microglia.
[Acta Pharmacologica Sinica]
6445218 XVQKL38S items 1 apa default asc 1
1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis | Acta Pharmacologica Sinica. (n.d.). Retrieved March 1, 2021, from https://www.nature.com/articles/s41401-021-00613-8 Cite
To support the discovery of new drug candidates for melanoma, scientists examined 180 metabolic modulators, including phytochemicals and anti-diabetic compounds, for their growth-inhibitory activities against melanoma cells, alone and in combination with the BRAF inhibitor vemurafenib. 4-methylumbelliferone and ursolic acid, were subjected to validation and further characterization.
6606345 QNU9QRLY items 1 apa default asc 1
Abildgaard, C., Rizza, S., Christiansen, H., Schmidt, S., Dahl, C., Abdul-Al, A., Christensen, A., Filomeni, G., & Guldberg, P. (2021). Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma. Scientific Reports, 11(1), 4390. https://doi.org/10.1038/s41598-021-83796-8 Cite
Seventeen key drivers of the gene subnetworks associated with poor prognosis, including the transcription factor ZNF180, are tested for their pro-tumorigenic effects in vitro. The anti-tumor effect of silencing ZNF180 is further validated using in vivo xenografts.
6606345 662QX4LN items 1 apa default asc 1
Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis | Nature Communications. (n.d.). Retrieved March 1, 2021, from https://www.nature.com/articles/s41467-021-21457-0 Cite
MediWound Ltd. announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer.
6606345 nan items 1 apa default asc 1
Through modeling 5‐FU response of murine colon and melanoma tumors, the authors report that effective reduction of tumor burden by 5‐FU was dependent on anti‐tumor immunity triggered by the activation of cancer‐cell‐intrinsic STING.
6445218 VDM537HW items 1 apa default asc 1
Tian, J., Zhang, D., Kurbatov, V., Wang, Q., Wang, Y., Fang, D., Wu, L., Bosenberg, M., Muzumdar, M. D., Khan, S., Lu, Q., Yan, Q., & Lu, J. (2021). 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING. The EMBO Journal, n/a(n/a), e106065. https://doi.org/10.15252/embj.2020106065 Cite
SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma at high risk of disease-related fatality.
6606345 8WP88AAS items 1 apa default asc 1
Scientists report that patients with low melanoma neoantigen burdens who responded to ICI had tumors with higher expression of pigmentation-related genes.
[Science Translational Medicine]
6445218 92EHJZ3B items 1 apa default asc 1
Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., Raghavan, R., Allouche, J., Kasumova, G., Frederick, D. T., Pauken, K. E., Weng, Q. Y., Silva, M. P. da, Xu, Y., Sande, A. A. J. van der, … Fisher, D. E. (2021). Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine, 13(581). https://doi.org/10.1126/scitranslmed.abd8636 Cite